Moderna has had a tumultuous period with its stock down nearly 44% in Q3, drawing the attention of Rosen Law Firm urging stockholders with large losses to contact them. Despite this, Moderna's
mRNA vaccines continue to differentiate themselves in the race against COVID-19. Moderna recently
dosed its first subject in the phase III trial for mRNA
norovirus vaccine in US while fending off a patent lawsuit by Alnylam. The
U.S government awarded Moderna $176 million to develop an mRNA bird flu pandemic vaccine. Their first mRNA Mpox vaccine proved to be more effective than rival vaccines in early testing. Moderna also
appointed Abbas Hussain to its board and despite recent setbacks, the company is thought to have promise as a buy on the dip.
Positive phase III data was also announced for their combo of Covid-19/Influenza mRNA vaccine and Moderna even secured links with Mitsubishi Tanabe in Japan. Despite taking a $1B hit, the company paused plans for a Kenyan mRNA vaccine plant in response to waning COVID vaccine demand.
Moderna MRNA News Analytics from Fri, 01 Mar 2024 08:00:00 GMT to Sat, 05 Oct 2024 23:01:00 GMT -
Rating -8
- Innovation 7
- Information 6
- Rumor -3
